January 18, 2016 – Autonomic Technologies, Inc. (“ATI”), a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache, secured expansion financing from CRG, a premier healthcare investment firm. ATI has developed the Pulsante™ SPG Microstimulator System to provide on-demand Sphenopalatine Ganglion (“SPG”) stimulation therapy with the intention to relieve the acute debilitating pain of cluster headache. Pulsante is a minimally-invasive, rechargeable, multi-channel, peripheral nerve stimulation system.
“We are pleased to have the support of CRG, an investment partner renowned for its strategic investments in healthcare,” said Gary Burbach, CEO of ATI. “This flexible financing will allow us to expand the commercial reach of Pulsante and continue our clinical work in additional indications and geographies.”
“We believe that ATI’s novel microstimulation therapy provides significant benefit to patients suffering from cluster headache relative to existing therapies and technologies,” said Nate Hukill, President of CRG. “We are excited to partner with ATI as this innovative company offers an important new treatment alternative for patients suffering from the debilitating effects of cluster headache.”
The Pulsante Microstimulator offers on-demand stimulation of the SPG that is known to play a critical role in cluster headache. The minimally invasive device is the first and only neuromodulation therapy that provides acute benefit along with a noted reduction in cluster headaches without any systemic side effects. Supported by long-term clinical data, Pulsante has received a CE mark for both chronic and episodic cluster headache.
About Autonomic Technologies
Autonomic Technologies is a medical device company headquartered in the San Francisco Bay Area with offices in Germany and Switzerland, focused on the development and commercialization of innovative therapies for the treatment of autonomic disorders, particularly severe headache. The company’s initial product, the Pulsante Microstimulator, is CE marked in Europe for the treatment of cluster headache. The device is under an IDE study in the U.S. for the treatment of chronic cluster headache. For additional information, please visit www.pulsante.eu or www.ati-spg.com
Founded in 2003, CRG (previously known as Capital Royalty L.P.) is a healthcare-focused investment firm with over $2 billion of assets under management that provides capital to healthcare companies primarily through structured debt and senior secured loans. CRG works across the spectrum of life science products and technologies and targets investment sizes ranging between $20 million and $300 million. The firm partners with commercial-stage healthcare companies to provide flexible financing solutions so they can achieve their growth objectives. CRG is headquartered in Houston, Texas with offices in Boulder, Colorado and New York City. For additional information, please visit www.crglp.com
Contact for CRG: